{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:30:14Z","timestamp":1790991014428,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess the efficacy of different preventive dental visits and treatments in reducing the risk of medication-related osteonecrosis of the jaws (MRONJ).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective study, patients diagnosed with MRONJ were divided into 5 groups based on available data: no preventive dental visits (group 0); dental visits and compliance with recommended treatments, at the university hospital\u2019s dental clinic (group 1) or maxillofacial surgery unit (group 2), or at a private dentist\u2019s (group 3); dental visits at one of the above and noncompliance with proposed treatments (group 4); patients judged eligible by the oncologist on panoramic radiography (group 5). Patients were classified on severity of MRONJ according to the Italian SIPMO\/SICMF 2.0 staging system. A descriptive analysis was performed on the results. Fisher\u2019s exact test was applied (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ninety-three patients diagnosed with MRONJ were considered for the study, but 22 were excluded due to a lack of data, leaving a sample of 71 cases. MRONJ staging was only 0 for some patients (26.92%) in group 0. In all groups, the majority of patients had stage 2 MRONJ. The proportions of cases in stage 3 were 7.69% in group 0, 18.18% in group 3, and 43.48% in group 5. Groups 0 and 3 were somewhat similar as regard MRONJ staging. Most patients in group 5 had MRONJ stage 2 or 3. No statistically significant differences emerged between the groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Preventive dental care can reduce the risk of MRONJ providing patients comply with the specialist\u2019s recommendations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-021-06587-x","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T22:03:38Z","timestamp":1632780218000},"page":"1723-1729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6956-6227","authenticated-orcid":false,"given":"Christian","family":"Bacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cerrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bardhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma Ahcene","family":"Djaballah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Sivolella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"issue":"1","key":"6587_CR1","first-page":"37","volume":"4","author":"SL Ruggiero","year":"2007","unstructured":"Ruggiero SL (2007) Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin Cases Miner Bone Metab 4(1):37\u201342","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"3","key":"6587_CR2","first-page":"221","volume":"48","author":"KH Taylor","year":"2010","unstructured":"Taylor KH, Middlefell LS (2010) Mizen KD Osteonecrosis of the jaws induced by anti-RANK ligand therapy Br J Oral Maxillofac Surg 48(3):221\u2013223","journal-title":"Mizen KD Osteonecrosis of the jaws induced by anti-RANK ligand therapy Br J Oral Maxillofac Surg"},{"key":"6587_CR3","doi-asserted-by":"crossref","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938\u201356. Erratum in: J Oral Maxillofac Surg. 2015 Jul;73(7):1440. Erratum in: J Oral Maxillofac Surg. 2015;73(9):1879.","DOI":"10.1016\/j.joms.2014.04.031"},{"issue":"2","key":"6587_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/2231-0762.178742","volume":"6","author":"D Rosella","year":"2016","unstructured":"Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G (2016) Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent 6(2):97\u2013104","journal-title":"J Int Soc Prev Community Dent"},{"issue":"2","key":"6587_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jocd.2008.02.002","volume":"11","author":"PD Delmas","year":"2008","unstructured":"Delmas PD (2008) Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 11(2):325\u2013338","journal-title":"J Clin Densitom"},{"issue":"9768","key":"6587_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813\u2013822","journal-title":"Lancet"},{"key":"6587_CR7","first-page":"147","volume":"1","author":"G Tenore","year":"2014","unstructured":"Tenore G, Palaia G, Gaimari G, Brugnoletti O, Bove L, Lo Giudice R et al (2014) Medication-related osteonecrosis of the jaws (MRONJ): etiological update. Senses Sci. 1:147\u201352","journal-title":"Senses Sci."},{"issue":"1","key":"6587_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, S\u00e1ndor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP (2015) Compston J International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 30(1):3\u201323","journal-title":"J Bone Miner Res."},{"key":"6587_CR9","unstructured":"Campisi G, Bedogni A, Fusco V. Raccomandazioni clinico-terapeutiche sull\u2019osteonecrosi delle ossa mascellari (ONJ) farmaco-relata e sua prevenzione (Version 2.0; July 2020)"},{"issue":"8","key":"6587_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1055\/s-0033-1348898","volume":"29","author":"A Bedogni","year":"2013","unstructured":"Bedogni A, Anesi A, Fior A, Bettini G, Nocini PF (2013) Microsurgical reconstruction of the mandible in a patient with Evans syndrome: a case report and review of the literature. J Reconstr Microsurg 29(8):545\u2013550","journal-title":"J Reconstr Microsurg"},{"issue":"5","key":"6587_CR11","first-page":"e595","volume":"21","author":"FJ Rodriguez-Lozano","year":"2016","unstructured":"Rodriguez-Lozano FJ, O\u00f1ate-S\u00e1nchez RE (2016) Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Med Oral Patol Oral Cir Bucal 21(5):e595-600","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"2","key":"6587_CR12","first-page":"e6944","volume":"12","author":"NA AlDhalaan","year":"2020","unstructured":"AlDhalaan NA, BaQais A, Al-Omar A (2020) Medication-related osteonecrosis of the jaw: a review. Cureus. 12(2):e6944","journal-title":"Cureus."},{"issue":"3","key":"6587_CR13","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jbmr.3017","volume":"32","author":"HY Kim","year":"2017","unstructured":"Kim HY, Kim JW, Kim SJ, Lee SH, Lee HS (2017) Uncertainty of current algorithm for bisphosphonate-related osteonecrosis of the jaw in population-based studies: a systematic review. J Bone Miner Res 32(3):584\u2013591","journal-title":"J Bone Miner Res"},{"issue":"4","key":"6587_CR14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.joms.2013.12.007","volume":"72","author":"ER Carlson","year":"2014","unstructured":"Carlson ER (2014) Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg 72(4):655\u2013657","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"6587_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jcms.2014.11.014","volume":"43","author":"O Ristow","year":"2015","unstructured":"Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C (2015) Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg 43(2):290\u2013293","journal-title":"J Craniomaxillofac Surg"},{"issue":"8","key":"6587_CR16","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.4065\/81.8.1100","volume":"81","author":"D Kademani","year":"2006","unstructured":"Kademani D, Koka S, Lacy MQ, Rajkumar SV (2006) Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 81(8):1100\u20131103","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"6587_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/dj4040045","volume":"4","author":"G Catania","year":"2016","unstructured":"Catania G, Monaco F, Limberti G, Alessio M, De Martino I, Barile C, Fasciolo A, Baraldi A, Ladetto M, Fusco V (2016) Osteonecrosis of the jaws (ONJ) after bisphosphonate treatment in patients with multiple myeloma: decreasing ONJ incidence after adoption of preventive measures. Dent J (Basel) 4(4):45","journal-title":"Dent J (Basel)"},{"key":"6587_CR18","doi-asserted-by":"crossref","unstructured":"Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, Sipmo Onj Board, Campisi G. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int. 2018;2018:2684924","DOI":"10.1155\/2018\/2684924"},{"key":"6587_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti CI, Maniezzo M, Campa T et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bony metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137\u2013145","journal-title":"Ann Oncol"},{"issue":"1","key":"6587_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdn554","volume":"20","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20(1):117\u2013120","journal-title":"Ann Oncol"},{"key":"6587_CR21","doi-asserted-by":"crossref","unstructured":"Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H; American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142(11):1243-51.","DOI":"10.14219\/jada.archive.2011.0108"},{"key":"6587_CR22","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"RE Marx","year":"2005","unstructured":"Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567\u20131575","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"6587_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/iej.12018","volume":"46","author":"AT Moinzadeh","year":"2013","unstructured":"Moinzadeh AT, Shemesh H, Neirynck NA, Aubert C, Wesselink PR (2013) Bisphosphonates and their clinical implications in endodontic therapy. Int Endod J 46(5):391\u2013398","journal-title":"Int Endod J"},{"issue":"2","key":"6587_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","volume":"127","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Schi\u00f8dt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T (2019) Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 127(2):117\u2013135","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6587_CR25","unstructured":"American Association of Endodontists. Endodontic implication of bisphosphonate-associated osteonecrosis of the jaws. 2010. Chicago, IL: American Association of Endodontists; https:\/\/www.aae.org\/specialty\/wp-content\/uploads\/sites\/2\/2017\/07\/bisphosonatesstatement.pdf (retrieved on internet on the 11th February 2021)"},{"issue":"5","key":"6587_CR26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/sj.bdj.2017.225","volume":"222","author":"A Muthukrishnan","year":"2017","unstructured":"Muthukrishnan A, Al-Ismail S, Bertelli G, Browne P (2017) MRONJ risk reduction pathway - 360 degree survey. Br Dent J 222(5):386\u2013390","journal-title":"Br Dent J"},{"key":"6587_CR27","unstructured":"Cerrato A, Zanette G, Boccuto M, Angelini A, Valente M, Bacci C. Actinomyces and MRONJ: a retrospective study and a literature review. J Stomatol Oral Maxillofac Surg. 2020;20:S2468\u20137855(20)30175\u20130"},{"issue":"5","key":"6587_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527\u2013534","journal-title":"J Oral Maxillofac Surg"},{"issue":"16","key":"6587_CR29","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.3390\/ijerph17165998","volume":"17","author":"G Campisi","year":"2020","unstructured":"Campisi G, Mauceri R, Bertoldo F, Bettini G, Biasotto M, Colella G, Consolo U, Di Fede O, Favia G, Fusco V, Gabriele M, Lo Casto A, Lo Muzio L, Marcian\u00f2 A, Mascitti M, Meleti M, Mignogna MD, Oteri G, Panzarella V, Romeo U, Santarelli A, Vescovi P, Marchetti C, Bedogni A (2020) Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian Consensus Update 2020. Int J Environ Res Public Health 17(16):5998","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"6587_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s13139-018-0533-x","volume":"52","author":"CH Lee","year":"2018","unstructured":"Lee CH, Son SH, Hong CM, Jeong JH, Jeong SY, Lee SW, Lee J, Kwon TG, Ahn BC (2018) Prevalence and risk factors of atypical femoral fracture bone scintigraphic feature in patients experiencing bisphosphonate-related osteonecrosis of the jaw. Nucl Med Mol Imaging 52(4):311\u2013317","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"6587_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.coms.2015.06.003","volume":"27","author":"TB Dodson","year":"2015","unstructured":"Dodson TB (2015) The Frequency of Medication-related osteonecrosis of the jaw and its associated risk factors. Oral Maxillofac Surg Clin North Am 27(4):509\u2013516","journal-title":"Oral Maxillofac Surg Clin North Am"},{"issue":"10","key":"6587_CR32","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/cam4.1173","volume":"6","author":"P Corraini","year":"2017","unstructured":"Corraini P, Heide-J\u00f8rgensen U, Schi\u00f8dt M, N\u00f8rholt SE, Acquavella J, S\u00f8rensen HT, Ehrenstein V (2017) Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark. Cancer Med 6(10):2271\u20132277","journal-title":"Cancer Med"},{"issue":"1","key":"6587_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/annonc\/mdr039","volume":"23","author":"AM Vandone","year":"2012","unstructured":"Vandone AM, Donadio M, Mozzati M, Ardine M, Polimeni MA, Beatrice S, Ciuffreda L, Scoletta M (2012) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 23(1):193\u2013200","journal-title":"Ann Oncol"},{"issue":"5","key":"6587_CR34","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","volume":"44","author":"R Fliefel","year":"2015","unstructured":"Fliefel R, Tr\u00f6ltzsch M, K\u00fchnisch J, Ehrenfeld M, Otto S (2015) Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 44(5):568\u2013585","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"6","key":"6587_CR35","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826\u2013836","journal-title":"J Bone Miner Res"},{"issue":"12","key":"6587_CR36","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","volume":"18","author":"F Jadu","year":"2007","unstructured":"Jadu F, Lee L, Pharoah M, Reece D, Wang L (2007) A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18(12):2015\u20132019","journal-title":"Ann Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06587-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06587-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06587-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T06:06:27Z","timestamp":1645509987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06587-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["6587"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06587-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to add the missing compact agreement Open Access funding note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was approved by the Ethics Committee for Clinical Trials (CESC) at Padua University Hospital (n\u00b08628 10.02.2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients gave consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients gave consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}